CA2572133A1 - Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis - Google Patents

Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis Download PDF

Info

Publication number
CA2572133A1
CA2572133A1 CA002572133A CA2572133A CA2572133A1 CA 2572133 A1 CA2572133 A1 CA 2572133A1 CA 002572133 A CA002572133 A CA 002572133A CA 2572133 A CA2572133 A CA 2572133A CA 2572133 A1 CA2572133 A1 CA 2572133A1
Authority
CA
Canada
Prior art keywords
antibody
substituted
antibodies
amino acid
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002572133A
Other languages
English (en)
French (fr)
Inventor
William Dall'acqua
Herren Wu
Melissa Damschroder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2572133A1 publication Critical patent/CA2572133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002572133A 2004-06-25 2005-06-24 Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis Abandoned CA2572133A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58318404P 2004-06-25 2004-06-25
US60/583,184 2004-06-25
US62415304P 2004-11-02 2004-11-02
US60/624,153 2004-11-02
PCT/US2005/022738 WO2006004663A2 (en) 2004-06-25 2005-06-24 Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis

Publications (1)

Publication Number Publication Date
CA2572133A1 true CA2572133A1 (en) 2006-01-12

Family

ID=35783288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002572133A Abandoned CA2572133A1 (en) 2004-06-25 2005-06-24 Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis

Country Status (6)

Country Link
US (2) US20060019342A1 (enExample)
EP (1) EP1773391A4 (enExample)
JP (1) JP2008504289A (enExample)
AU (1) AU2005259992A1 (enExample)
CA (1) CA2572133A1 (enExample)
WO (1) WO2006004663A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802338A4 (en) * 2004-10-18 2010-01-27 Medimmune Inc CELL SEALING PROCESS FOR THE GROWTH OF LISTERIES
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2008015568A (es) 2006-06-08 2009-01-13 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias.
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
TWI556826B (zh) * 2007-02-23 2016-11-11 貝勒研究協會 經由樹突狀細胞凝集素樣氧化型低密度脂蛋白受體－１（ｌｏｘ－１）之人類抗原呈現細胞活化
WO2009023760A1 (en) * 2007-08-14 2009-02-19 Smithkline Beechan Corporation Novel methods and cell lines
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
MX336725B (es) * 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
MY177564A (en) 2007-12-05 2020-09-20 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof
TWI441649B (zh) 2007-12-05 2014-06-21 Chugai Pharmaceutical Co Ltd Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
CA2721052C (en) * 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI599577B (zh) * 2008-09-26 2017-09-21 Chugai Pharmaceutical Co Ltd Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
AU2010258094B2 (en) * 2009-06-10 2013-09-05 Stephen Sanig Research Institute Ltd. Methods of generating cells exhibiting phenotypic plasticity
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CA2779384C (en) * 2009-11-04 2018-02-27 Schering Corporation Engineered anti-tslp antibody
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
EP2889377B1 (en) 2012-08-24 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Fcyriib-specific fc region variant
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3142691A4 (en) 2014-05-16 2018-04-11 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RS62749B1 (sr) 2014-12-19 2022-01-31 Chugai Pharmaceutical Co Ltd Anti-c5 antitela i načini njihove upotrebe
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
ES3036076T3 (en) 2015-04-14 2025-09-12 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
TW201735947A (zh) 2016-03-14 2017-10-16 Chugai Pharmaceutical Co Ltd 用於癌之治療的細胞傷害誘導治療劑
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
IL274265B1 (en) 2017-11-01 2025-09-01 Chugai Pharmaceutical Co Ltd Variant and isoform of an antibody with attenuated biological activity
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
GB201820006D0 (en) 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU675916B2 (en) * 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DE69621940T2 (de) * 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
TWI335821B (en) * 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
WO2005035575A2 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies

Also Published As

Publication number Publication date
US20100145028A1 (en) 2010-06-10
EP1773391A2 (en) 2007-04-18
US20060019342A1 (en) 2006-01-26
JP2008504289A (ja) 2008-02-14
AU2005259992A1 (en) 2006-01-12
EP1773391A4 (en) 2009-01-21
WO2006004663A3 (en) 2006-06-15
WO2006004663A2 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
US20100145028A1 (en) Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed Mutagenesis
AU2011201507B2 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
CA2685222C (en) Methods of reducing eosinophil levels
KR102690998B1 (ko) 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도
AU2017285764B2 (en) Anti-myostatin antibodies and methods of use
DK2897978T3 (en) PROCEDURES FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY
TW202124415A (zh) 抗ｔｎｆｒ２抗體及使用方法
US11773176B2 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
TW202321304A (zh) 抗ｃｃｒ８抗體
WO2021228091A1 (zh) St2抗原结合蛋白
CA2685213A1 (en) Engineered rabbit antibody variable domains and uses thereof
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
HK1206036B (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
HK1131033B (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
HK1211306B (en) Methods for identifying antibodies with reduced immunogenicity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued